National Institute for Occupational Safety and Health; Proposed Changes to the Dose Reconstruction Target Organ Selection for Lymphoma Under the Energy Employees Occupational Illness Compensation Program Act of 2000, 3095-3096 [E6-542]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 12 / Thursday, January 19, 2006 / Notices
public attendance and comment. Any
individual who wishes to attend the
meeting and/or participate in the public
comment session should e-mail
nvac@osophs.dhhs.gov or call 202–690–
5566.
Dated: January 11, 2006.
Bruce Gellin,
Director, National Vaccine Program Office.
[FR Doc. 06–493 Filed 1–18–06; 8:45 am]
BILLING CODE 4150–44–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Institute for Occupational
Safety and Health; Proposed Changes
to the Dose Reconstruction Target
Organ Selection for Lymphoma Under
the Energy Employees Occupational
Illness Compensation Program Act of
2000
Authority: 42 CFR 82.32, 67 FR 22335–
22336.
Department of Health and
Human Services (HHS), Centers for
Disease Control and Prevention (CDC).
AGENCY:
sroberts on PROD1PC70 with NOTICES
ACTION:
Notice for public comment.
SUMMARY: The National Institute for
Occupational Safety and Health
(NIOSH) proposes to change the
selection of target organs used in dose
reconstructions NIOSH produces under
the Energy Employees Occupational
Illness Compensation Program Act of
2000 (EEOICPA) for energy employees
with lymphoma cancers. This proposed
change is in response to an evaluation
by NIOSH of current scientific data on
lymphoma, which revealed that the site
of the radiation injury can differ from
the site of the tumor or cancer origin
documented in the medical files of a
lymphoma cancer patient. The new
process for selecting dose reconstruction
target organs for energy employees with
lymphoma cancers would include
selecting the target organ that would
have received the highest radiation dose
from among relevant, possibly irradiated
organs, as determined through the dose
reconstruction process, when the
identity of the target organ is in
question. This change would result in
the Department of Labor calculating
higher probability of causation
determinations for select lymphoma
cases among previously decided and
current EEOICPA cancer claims.
NIOSH must receive public
comments on this proposed change on
DATES:
VerDate Aug<31>2005
16:38 Jan 18, 2006
Jkt 208001
or before 15 days after the date of
publication in the Federal Register.
ADDRESSES: Mail comments concerning
this proposed change to Larry Elliott,
Director, Office of Compensation
Analysis and Support, National Institute
for Occupational Safety and Health,
4676 Columbia Parkway, Mailstop C–46,
Cincinnati, Ohio 45226. Submit
electronic comments to
OCAS@CDC.GOV.
FOR FURTHER INFORMATION CONTACT:
Larry Elliott, Director, Office of
Compensation Analysis and Support,
National Institute for Occupational
Safety and Health, 4676 Columbia
Parkway, Mailstop C–46, Cincinnati, OH
45226, Telephone: (513) 533–6800 (This
is not a toll-free number).
SUPPLEMENTARY INFORMATION: NIOSH
conducts radiation dose reconstructions
under EEOICPA in compliance with the
dose reconstruction methods specified
in HHS regulations at 42 CFR part 82.
These regulations provide for NIOSH to
update its dose reconstruction methods
as necessary on the basis of improved
scientific understanding and specify a
process for deciding and implementing
such updates (41 CFR 82.30–82.33).
Accordingly, NIOSH is currently
proposing to update its method for
reconstructing radiation doses in cases
involving certain lymphoma cancers.
Specifically, NIOSH is proposing to
change its method for identifying the
target organ for which radiation doses
will be reconstructed in these cases, for
the reasons described below. As
required for certain updates in dose
reconstruction methods, NIOSH will
present the proposed change to the
Advisory Board on Radiation and
Worker Health for its comments. NIOSH
will also consider all public comments
concerning this change that are received
prior to the comment deadline, as
specified above.
NIOSH has re-examined the
appropriateness of the current method
of selecting dosimetry target organs for
lymphoma cases in light of the current
scientific knowledge on the diagnosis
and etiology of the various forms of
lymphoma.1 This re-examination has
revealed that for many non-Hodgkin’s
1 Crowther, M. Consultant’s Report, Dose
Reconstruction Project. Prepared for the National
Institute for Occupational Safety and Health Office
of Compensation Analysis and Support. 2005;
Eckerman, K.F. Target Organs for Lymphatic and
Hematopoietic Cancers Comments/Suggestions.
Prepared for the National Institute for Occupational
Safety and Health Office of Compensation Analysis
and Support. 2005. Available online at: https://
www.cdc.gov/niosh/ocas/ocasdose.html. (This
information can be found on the aforementioned
Web page under the ‘‘Miscellaneous Items’’ heading
in the section ‘‘Evaluation of Target Organ for
Lymphomas.’’)
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
3095
lymphomas, there are two problems
with NIOSH’s current target organ
selection method. First, the site of
occurrence of the tumor is not
necessarily the site of the original
radiation injury. Second, the site listed
in the diagnosis may not actually be the
site of primary involvement. Rather, it is
common to list the site of the biopsy,
which may be selected on the basis of
medical considerations in terms of the
clinical symptoms and condition of the
patient and the ease of surgical access.
Both of these problems contribute to the
possibility that under current methods
for select lymphoma cases, NIOSH is
not certain to be basing its dose
reconstruction on the organ that has the
highest radiation dose and may have
been the site of origin of the lymphoma
of the energy employee.
As a result of this re-evaluation,
NIOSH proposes to modify the selection
of target organs in select lymphoma
cases so that the organ that would have
received the highest radiation dose from
among relevant, possibly irradiated
organs, as determined through the dose
reconstruction process, is used in the
dose reconstruction. For the subset of
lymphomas where tumor location is
informative about the probable site of
the original radiation injury (e.g.
Hodgkin’s disease, lymphosarcoma,
etc.), information related to the site of
diagnosis would be considered in target
organ selection.
This proposed change pertains only to
the selection of the appropriate target
organ as the site of radiation injury (i.e.,
for calculation of effective radiation
dose during the dose reconstruction
process). It has no bearing on the
selection of the appropriate Interactive
Radiological Epidemiology Program
(IREP) cancer risk model for
determining probability of causation,
nor does it impact the cancer risk
models themselves.
This proposed change in NIOSH dose
reconstruction methods would be likely
to have a substantial effect on certain
EEOICPA cancer cases involving
lymphomas. NIOSH would review all
relevant completed dose reconstructions
for cases that have not been
compensated to identify those for which
this new method is applicable, and
would re-complete these dose
reconstructions using this new method,
and would apply this new method to all
current and future cases undergoing
dose reconstruction. Application of this
new method would result in the
Department of Labor calculating higher
probability of causation determinations
for select lymphoma cases among
previously decided and current
EEOICPA cancer claims.
E:\FR\FM\19JAN1.SGM
19JAN1
3096
Federal Register / Vol. 71, No. 12 / Thursday, January 19, 2006 / Notices
The proposed change may be
discussed at meetings of the Advisory
Board on Radiation and Worker Health
on January 9, 2006 (teleconference) and
January 24–26, 2006 in Oak Ridge, TN.
Only after the close of the public
comment period will NIOSH make a
final decision regarding the proposed
change.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: January 12, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–538 Filed 1–18–06; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: January 10, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention (CDC).
[FR Doc. E6–543 Filed 1–18–06; 8:45 am]
BILLING CODE 4163–18–P
Dated: January 10, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–542 Filed 1–18–06; 8:45 am]
Centers for Disease Control and
Prevention
BILLING CODE 4163–18–P
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following federal
advisory committee meeting:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Portfolio
Review of Single Gene Disorders and
Disability
sroberts on PROD1PC70 with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting:
Name: Disease, Disability, and Injury
Prevention and Control Special Emphasis
Panel (SEP): Portfolio Review of Single Gene
Disorders and Disability.
Times and Dates: 9 a.m.–5 p.m., February
10, 2006 (Closed).
Place: National Center on Birth Defects and
Developmental Disabilities, CDC, 12
Executive Park Drive, Atlanta, GA 30329,
Telephone Number 404.498.3800.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters to be Discussed: The meeting will
include the review and discussion of the
Single Gene Disorders and Disability Team’s
strategies and activities.
For Further Information Contact: Esther
Sumartojo, Acting Associate Director for
Science and Public Health, National Center
on Birth Defects and Developmental
Disabilities, CDC, 1600 Clifton Road, NE.,
Mailstop E–87, Atlanta, GA 30333,
Telephone Number 404.498.3800.
VerDate Aug<31>2005
16:38 Jan 18, 2006
Jkt 208001
Developmental Disabilities, CDC, 1600
Clifton Road, NE., (E–86), Atlanta, Georgia
30333, telephone 404/498–3926, fax 404/
498–3550.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both the CDC and Agency for Toxic
Substances and Disease Registry.
National Task Force on Fetal Alcohol
Syndrome and Fetal Alcohol Effect:
Meeting
Name: National Task Force on Fetal
Alcohol Syndrome and Fetal Alcohol Effect
(NTFFASFAE).
Times and Dates: 8:30 a.m.–4:30 p.m.,
February 16, 2006. 8:30 a.m.–1 p.m.,
February 17, 2006.
Place: Embassy Suites Hotel Buckhead,
3285 Peachtree Road, NE., Atlanta, Georgia
30305, telephone 404/261–7733, fax 404/
262–0522.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 65 people.
Purpose: The Secretary is authorized by the
Public Health Service Act, section 399G (42
U.S.C. Section 280f, as added by Pub. L. 105–
392), to establish a NTFFASFAE to: (1) Foster
coordination among all governmental
agencies, academic bodies and community
groups that conduct or support Fetal Alcohol
Syndrome (FAS) and Fetal Alcohol Effect
(FAE) research, programs and surveillance;
and (2) to otherwise meet the general needs
of populations actually or potentially
impacted by FAS and FAE.
Matters to be Discussed: Agenda items
include: (1) Discussion of the Task Force’s
Post-Exposure working group activities; (2)
presentations regarding prevention initiatives
from other relevant health topics such as
tobacco use and HIV; (3) presentation and
discussion regarding evidence-based review
of FAS prevention strategies; (4) Task Force
next steps; (5) updates from the Interagency
Coordinating Committee on FAS, CDC, and
other federal agencies, and liaison members;
(6) and scheduling of the next meeting.
Agenda items are subject to change as
priorities dictate.
For Further Information Contact: Mary
Kate Weber, M.P.H., Executive Secretary,
National Center on Birth Defects and
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Immunization
Practices: Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC) announce
the following Federal committee
meeting.
Name: Advisory Committee on
Immunization Practices (ACIP).
Time and Date: 8 a.m.–6:15 p.m., February
21, 2006.
8 a.m.–5 p.m., February 22, 2006.
Place: Centers for Disease Control and
Prevention, 1600 Clifton Road, NE., Building
19, Room 232, Atlanta, Georgia 30333.
Status: Open to the public, limited only by
the space available.
Purpose: The committee is charged with
advising the Director, CDC, on the
appropriate uses of immunizing agents. In
addition, under 42 U.S.C. 1396s, the
committee is mandated to establish and
periodically review and, as appropriate,
revise the list of vaccines for administration
to vaccine-eligible children through the
Vaccines for Children (VFC) program, along
with schedules regarding the appropriate
periodicity, dosage, and contraindications
applicable to the vaccines.
Matters To Be Discussed: The agenda will
include discussions on Rotavirus Vaccine
which may include a possible VFC Vote;
Human Papillomavirus Vaccine; general
recommendations on immunization;
Influenza; Herpes Zoster Vaccine; Tetanus
Toxoid, Diphtheria Toxoid, and Acellular
Pertussis (Tdap) Vaccines; and departmental
updates.
Agenda items are subject to change as
priorities dictate.
For Further Information Contact: Demetria
Gardner, Epidemiology and Surveillance
Division, National Immunization Program,
CDC, 1600 Clifton Road, NE., (E–61), Atlanta,
Georgia 30333, telephone 404/639–8096, fax
404/639–8616.
E:\FR\FM\19JAN1.SGM
19JAN1
]]>Agencies
[Federal Register Volume 71, Number 12 (Thursday, January 19, 2006)]
[Notices]
[Pages 3095-3096]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-542]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Institute for Occupational Safety and Health; Proposed
Changes to the Dose Reconstruction Target Organ Selection for Lymphoma
Under the Energy Employees Occupational Illness Compensation Program
Act of 2000
Authority: 42 CFR 82.32, 67 FR 22335-22336.
AGENCY: Department of Health and Human Services (HHS), Centers for
Disease Control and Prevention (CDC).
ACTION: Notice for public comment.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) proposes to change the selection of target organs used in dose
reconstructions NIOSH produces under the Energy Employees Occupational
Illness Compensation Program Act of 2000 (EEOICPA) for energy employees
with lymphoma cancers. This proposed change is in response to an
evaluation by NIOSH of current scientific data on lymphoma, which
revealed that the site of the radiation injury can differ from the site
of the tumor or cancer origin documented in the medical files of a
lymphoma cancer patient. The new process for selecting dose
reconstruction target organs for energy employees with lymphoma cancers
would include selecting the target organ that would have received the
highest radiation dose from among relevant, possibly irradiated organs,
as determined through the dose reconstruction process, when the
identity of the target organ is in question. This change would result
in the Department of Labor calculating higher probability of causation
determinations for select lymphoma cases among previously decided and
current EEOICPA cancer claims.
DATES: NIOSH must receive public comments on this proposed change on or
before 15 days after the date of publication in the Federal Register.
ADDRESSES: Mail comments concerning this proposed change to Larry
Elliott, Director, Office of Compensation Analysis and Support,
National Institute for Occupational Safety and Health, 4676 Columbia
Parkway, Mailstop C-46, Cincinnati, Ohio 45226. Submit electronic
comments to OCAS@CDC.GOV.
FOR FURTHER INFORMATION CONTACT: Larry Elliott, Director, Office of
Compensation Analysis and Support, National Institute for Occupational
Safety and Health, 4676 Columbia Parkway, Mailstop C-46, Cincinnati, OH
45226, Telephone: (513) 533-6800 (This is not a toll-free number).
SUPPLEMENTARY INFORMATION: NIOSH conducts radiation dose
reconstructions under EEOICPA in compliance with the dose
reconstruction methods specified in HHS regulations at 42 CFR part 82.
These regulations provide for NIOSH to update its dose reconstruction
methods as necessary on the basis of improved scientific understanding
and specify a process for deciding and implementing such updates (41
CFR 82.30-82.33). Accordingly, NIOSH is currently proposing to update
its method for reconstructing radiation doses in cases involving
certain lymphoma cancers. Specifically, NIOSH is proposing to change
its method for identifying the target organ for which radiation doses
will be reconstructed in these cases, for the reasons described below.
As required for certain updates in dose reconstruction methods, NIOSH
will present the proposed change to the Advisory Board on Radiation and
Worker Health for its comments. NIOSH will also consider all public
comments concerning this change that are received prior to the comment
deadline, as specified above.
NIOSH has re-examined the appropriateness of the current method of
selecting dosimetry target organs for lymphoma cases in light of the
current scientific knowledge on the diagnosis and etiology of the
various forms of lymphoma.\1\ This re-examination has revealed that for
many non-Hodgkin's lymphomas, there are two problems with NIOSH's
current target organ selection method. First, the site of occurrence of
the tumor is not necessarily the site of the original radiation injury.
Second, the site listed in the diagnosis may not actually be the site
of primary involvement. Rather, it is common to list the site of the
biopsy, which may be selected on the basis of medical considerations in
terms of the clinical symptoms and condition of the patient and the
ease of surgical access. Both of these problems contribute to the
possibility that under current methods for select lymphoma cases, NIOSH
is not certain to be basing its dose reconstruction on the organ that
has the highest radiation dose and may have been the site of origin of
the lymphoma of the energy employee.
---------------------------------------------------------------------------
\1\ Crowther, M. Consultant's Report, Dose Reconstruction
Project. Prepared for the National Institute for Occupational Safety
and Health Office of Compensation Analysis and Support. 2005;
Eckerman, K.F. Target Organs for Lymphatic and Hematopoietic Cancers
Comments/Suggestions. Prepared for the National Institute for
Occupational Safety and Health Office of Compensation Analysis and
Support. 2005. Available online at: https://www.cdc.gov/niosh/ocas/
ocasdose.html. (This information can be found on the aforementioned
Web page under the ``Miscellaneous Items'' heading in the section
``Evaluation of Target Organ for Lymphomas.'')
---------------------------------------------------------------------------
As a result of this re-evaluation, NIOSH proposes to modify the
selection of target organs in select lymphoma cases so that the organ
that would have received the highest radiation dose from among
relevant, possibly irradiated organs, as determined through the dose
reconstruction process, is used in the dose reconstruction. For the
subset of lymphomas where tumor location is informative about the
probable site of the original radiation injury (e.g. Hodgkin's disease,
lymphosarcoma, etc.), information related to the site of diagnosis
would be considered in target organ selection.
This proposed change pertains only to the selection of the
appropriate target organ as the site of radiation injury (i.e., for
calculation of effective radiation dose during the dose reconstruction
process). It has no bearing on the selection of the appropriate
Interactive Radiological Epidemiology Program (IREP) cancer risk model
for determining probability of causation, nor does it impact the cancer
risk models themselves.
This proposed change in NIOSH dose reconstruction methods would be
likely to have a substantial effect on certain EEOICPA cancer cases
involving lymphomas. NIOSH would review all relevant completed dose
reconstructions for cases that have not been compensated to identify
those for which this new method is applicable, and would re-complete
these dose reconstructions using this new method, and would apply this
new method to all current and future cases undergoing dose
reconstruction. Application of this new method would result in the
Department of Labor calculating higher probability of causation
determinations for select lymphoma cases among previously decided and
current EEOICPA cancer claims.
[[Page 3096]]
The proposed change may be discussed at meetings of the Advisory
Board on Radiation and Worker Health on January 9, 2006
(teleconference) and January 24-26, 2006 in Oak Ridge, TN. Only after
the close of the public comment period will NIOSH make a final decision
regarding the proposed change.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities for
both the Centers for Disease Control and Prevention and the Agency for
Toxic Substances and Disease Registry.
Dated: January 10, 2006.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E6-542 Filed 1-18-06; 8:45 am]
BILLING CODE 4163-18-P
